A study of more than 5,000 breast cancer patients found that multi-gene sequencing has rapidly replaced BRCA1/2-only tests, resulting in better pathogenic variant detection but also higher VUS rates.
The firm has developed microbubbles that bind to target molecules based on surface antibodies.
The similar analytic performance of LDTs and FDA-approved tests informs the ongoing debate about the regulation of in vitro testing.
The results showed overall high concordance between test results and whether patients received chemotherapy, with some relevant exceptions.
Muneesh Tewari, a former Fred Hutchinson Cancer Research Center scientist who recently moved to the University of Mic